disufenton sodium and Stroke

Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Humans; Neuroprotective Agents; Research; Research Design; Risk; Stroke

Topics: Animals; Benzenesulfonates; Brain; Callithrix; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Male; Mice; Neuroprotective Agents; Random Allocation; Rats; Stroke

Topics: Animals; Benzenesulfonates; Brain Neoplasms; Cyclic N-Oxides; DNA Damage; Guanine; Hearing Loss, Noise-Induced; HIV-1; Humans; Methylene Blue; Phototherapy; Reactive Oxygen Species; RNA Virus Infections; Stroke; West Nile virus

Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Chelating Agents; Clinical Trials as Topic; Combined Modality Therapy; Diffusion of Innovation; Disease Models, Animal; Drug Evaluation, Preclinical; Egtazic Acid; Hematopoietic Cell Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnesium; Minocycline; NADPH Oxidases; Neuroprotective Agents; Pregnatrienes; Serum Albumin; Stroke; Thrombolytic Therapy; Translational Research, Biomedical

Topics: Animals; Antioxidants; Azoles; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Humans; Hypothermia, Induced; Isoindoles; Neuroprotective Agents; Organoselenium Compounds; Stroke

Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Drug Industry; Humans; Nitrogen Oxides; Stroke

Topics: Animals; Behavior, Animal; Benzenesulfonates; Callithrix; Chlormethiazole; Cognition; Disease Models, Animal; Female; Male; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Psychomotor Performance; Pyridines; Recovery of Function; Stroke

Topics: Animals; Benzenesulfonates; Biochemistry; Clinical Trials as Topic; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Aged; Animals; Benzenesulfonates; Brain Ischemia; Humans; Middle Aged; Models, Cardiovascular; Neuroprotective Agents; Nitrogen Oxides; Stroke; Structure-Activity Relationship

Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Free Radical Scavengers; Humans; Models, Biological; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Animals; Benzenesulfonates; Brain; Drug Design; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Animals; Benzenesulfonates; Free Radicals; Humans; Male; Nitrogen Oxides; Rabbits; Rats; Stroke; Treatment Outcome

Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Isoindoles; Mice; Mice, Mutant Strains; Neuroprotective Agents; Nitrogen Oxides; Organoselenium Compounds; Pregnatrienes; Rats; Reactive Oxygen Species; Stroke; Treatment Failure; Treatment Outcome

Topics: Acute Disease; Animals; Benzenesulfonates; Clinical Trials as Topic; Contraindications; Drug Interactions; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Humans; Nitrogen Oxides; Stroke

Topics: Animals; Benzenesulfonates; Cardiovascular Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Nitrogen Oxides; Stroke; Thrombolytic Therapy

Topics: Animals; Benzenesulfonates; Brain; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; GABA Agonists; Humans; Neuroprotective Agents; Nitrogen Oxides; Piperidines; Randomized Controlled Trials as Topic; Sodium Channel Blockers; Stroke; Thiazoles; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator

Topics: Acute Disease; Benzenesulfonates; Biomarkers; Brain Damage, Chronic; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Disability Evaluation; Double-Blind Method; Free Radical Scavengers; Humans; Neuroprotective Agents; Neuropsychological Tests; Nitrogen Oxides; Randomized Controlled Trials as Topic; Sample Size; Severity of Illness Index; Statistics, Nonparametric; Stroke; Treatment Failure; Treatment Outcome

Topics: Animals; Benzenesulfonates; Cerebral Hemorrhage; Disease Models, Animal; Humans; Neuroprotective Agents; Protein Biosynthesis; Stroke; Thrombolytic Therapy

Topics: Benzenesulfonates; Humans; Membrane Proteins; Myocardial Revascularization; Neuroprotective Agents; Plasminogen Activators; Randomized Controlled Trials as Topic; Stroke; Tetraspanins; Tissue Plasminogen Activator

Topics: Animals; Benzenesulfonates; Cerebral Infarction; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Intracranial Embolism; Neuroprotective Agents; Reproducibility of Results; Research Design; Stroke

Topics: Animals; Benzenesulfonates; Brain Ischemia; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Stroke; Time Factors

Topics: Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Approval; Drug Design; Drug Industry; Endpoint Determination; Guidelines as Topic; Humans; Models, Cardiovascular; National Institutes of Health (U.S.); Patient Selection; Stroke; Treatment Outcome; United States; United States Food and Drug Administration

Topics: Animals; Benzenesulfonates; Clinical Trials, Phase III as Topic; Free Radical Scavengers; Humans; Neuroprotective Agents; Stroke; Treatment Outcome

Topics: Animals; Antihypertensive Agents; Antioxidants; Benzenesulfonates; Blood Pressure; Cardiovascular Agents; Coagulants; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Erythropoietin; Excitatory Amino Acid Antagonists; Factor VIIa; Hemostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Oxidative Stress; Signal Transduction; Stroke; Treatment Outcome

Topics: Acute Disease; Benzenesulfonates; Clinical Trials as Topic; Humans; Neuroprotective Agents; Stroke; Treatment Failure

Topics: Aspirin; Benzenesulfonates; Cardiomyopathies; Clopidogrel; Comorbidity; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Neuroprotective Agents; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; Stroke Volume; Thrombolytic Therapy; Ticlopidine

Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; GABA Agonists; Humans; Hypothermia; N-Methylaspartate; Narcotic Antagonists; Neuroprotective Agents; Stroke; Tissue Plasminogen Activator

Topics: Adult; Aged; Benzenesulfonates; Female; Free Radical Scavengers; Glomerular Filtration Rate; Half-Life; Humans; Infusions, Intravenous; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Nitrogen Oxides; Stroke

Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Free Radical Scavengers; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Nitrogen Oxides; Severity of Illness Index; Stroke; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Creatinine; Double-Blind Method; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Infusions, Intravenous; Nervous System Diseases; Neuroprotective Agents; Nitrogen Oxides; Severity of Illness Index; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome

Topics: Aged; Benzenesulfonates; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Stroke; Treatment Outcome

Topics: Adult; Benzenesulfonates; Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Nootropic Agents; Placebos; Stroke

Topics: Acute Disease; Aged; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Odds Ratio; Stroke; Time Factors; Treatment Failure

Topics: Age Factors; Aged; Antioxidants; Benzenesulfonates; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Comorbidity; Double-Blind Method; Drug Administration Schedule; Emergency Medical Services; Encephalitis; Female; Humans; Hyperglycemia; Injections, Intravenous; Male; Meta-Analysis as Topic; Middle Aged; Neuroprotective Agents; Placebos; Prognosis; Stroke; Treatment Failure

Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Membrane Glycoproteins; Metabolic Clearance Rate; Middle Aged; Neuroprotective Agents; Nitrogen Oxides; Severity of Illness Index; Stroke; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Trypsin Inhibitor, Kunitz Soybean

Topics: Animals; Antioxidants; Brain Ischemia; Cell Death; Cells, Cultured; Cholesterol; Ischemic Attack, Transient; Nervous System Diseases; Neurons; Neuroprotective Agents; Nitrogen Oxides; Rats; Reactive Oxygen Species; Reperfusion Injury; Stroke; Structure-Activity Relationship

Topics: Albumins; Antioxidants; Benzenesulfonates; Caffeine; Cerebral Hemorrhage; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ethanol; Fibrinolytic Agents; Glyburide; Humans; Magnesium; Neurons; Neuroprotective Agents; Recombinant Proteins; Reperfusion; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Failure

Topics: Animals; Benzenesulfonates; Disease Models, Animal; Humans; Neuroprotective Agents; Rats; Regional Blood Flow; Reproducibility of Results; Stroke

Topics: Benzenesulfonates; Cardiovascular Agents; Humans; Quality Control; Reproducibility of Results; Stroke; Treatment Outcome

Topics: Animals; Benzenesulfonates; Drug Evaluation, Preclinical; Female; Male; Meta-Analysis as Topic; Neuroprotective Agents; Stroke

Topics: Age Factors; Animals; Benzenesulfonates; Cardiovascular Agents; Data Interpretation, Statistical; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Humans; Multicenter Studies as Topic; Placebos; Random Allocation; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sex Factors; Stroke

Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Haplorhini; Humans; Neuroprotective Agents; Nitric Oxide; Stroke

Topics: Animals; Behavior, Animal; Benzenesulfonates; Callithrix; Cerebral Cortex; Chlormethiazole; Disease Models, Animal; Drug Administration Routes; Evaluation Studies as Topic; Extinction, Psychological; Motor Activity; Neostriatum; Neuroprotective Agents; Nitrogen Oxides; Pyridines; Space Perception; Stereotaxic Techniques; Stroke; Time Factors

Topics: Benzenesulfonates; Clinical Trials as Topic; Drug Industry; Free Radical Scavengers; Humans; Nitrogen Oxides; Stroke; Treatment Outcome

Topics: Animals; Benzenesulfonates; Callithrix; Disease Models, Animal; Drug Evaluation, Preclinical; Infarction, Middle Cerebral Artery; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Perceptual Disorders; Recovery of Function; Stroke; Time Factors; Treatment Outcome

Topics: Acute Disease; Animals; Benzenesulfonates; Central Nervous System; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Humans; Hypothermia, Induced; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Stroke; Tenecteplase; Time Factors; Tissue Plasminogen Activator

Topics: Animals; Behavior, Animal; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Intracranial Embolism; Male; Neuroprotective Agents; Nitrogen Oxides; Rabbits; Severity of Illness Index; Stroke; Tenecteplase; Time Factors; Tissue Plasminogen Activator

Topics: Benzenesulfonates; Humans; Magnetic Resonance Imaging; Nitrogen Oxides; Stroke; Time Factors; Tissue Plasminogen Activator; Tomography, X-Ray Computed

Topics: Acute Disease; Benzenesulfonates; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke

Topics: Benzenesulfonates; Fibrinolytic Agents; Global Health; Humans; Hypertension; Nitrogen Oxides; Obesity; Smoking; Smoking Prevention; Stroke; Tissue Plasminogen Activator

Topics: Benzenesulfonates; Brain Ischemia; Humans; Nervous System Diseases; Neurons; Nitrogen Oxides; Stroke

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 5-Lipoxygenase-Activating Proteins; Benzenesulfonates; Cardiovascular Agents; Carrier Proteins; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Membrane Proteins; Nitrogen Oxides; Stroke

Topics: Antioxidants; Benzenesulfonates; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Nitrogen Oxides; Stroke; Tissue Plasminogen Activator; Ultrasonic Therapy

Topics: Animals; Benzenesulfonates; Brain; Brain Ischemia; Clinical Trials as Topic; Diffusion Magnetic Resonance Imaging; Drug Design; Humans; Magnetic Resonance Angiography; Neuroprotective Agents; Patient Selection; Recombinant Proteins; Stroke; Time Factors; Tissue Plasminogen Activator; Tomography, X-Ray Computed

Topics: Anti-Inflammatory Agents; Benzenesulfonates; Drug Combinations; Free Radical Scavengers; Glucose; Hemorrhage; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Interferon beta-1a; Interferon-beta; Neuroprotective Agents; Potassium; Randomized Controlled Trials as Topic; Recombinant Proteins; Stroke; Tissue Plasminogen Activator

Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Hemorrhage; Humans; Nitrogen Oxides; Stroke

Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Humans; Nitrogen Oxides; Stroke

Topics: Animals; Antioxidants; Benzenesulfonates; Cerebrovascular Circulation; Drug Therapy, Combination; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke; Thrombolytic Therapy

Topics: Benzenesulfonates; Biomarkers; Clinical Trials, Phase III as Topic; Double-Blind Method; Fibrinolytic Agents; Free Radical Scavengers; Hemorrhage; Humans; Neuroprotective Agents; Nitrogen Oxides; Randomized Controlled Trials as Topic; Sample Size; Severity of Illness Index; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome

Topics: Animals; Benzenesulfonates; Callithrix; Chlormethiazole; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Fibrinolytic Agents; Free Radical Scavengers; Hemorrhage; Humans; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Nitrogen Oxides; Pyridines; Randomized Controlled Trials as Topic; Research Design; Rodentia; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome

Topics: Animals; Benzenesulfonates; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Drug Industry; Humans; Stroke

Topics: Acute Disease; Aspirin; Benzenesulfonates; Carotid Arteries; Clopidogrel; Dipyridamole; Europe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neuroprotective Agents; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Ticlopidine

Topics: Adverse Drug Reaction Reporting Systems; Benzenesulfonates; Cardiac Output, Low; Clinical Trials as Topic; Data Interpretation, Statistical; Free Radical Scavengers; Humans; Hypokalemia; Neuroprotective Agents; Research Design; Stroke

Topics: Benzenesulfonates; Cardiovascular Agents; Clinical Trials as Topic; Confidence Intervals; Humans; Neuroprotective Agents; Sample Size; Stroke

Topics: Animals; Apoptosis; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Nucleus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electron Transport Complex II; Free Radical Scavengers; Hydrogen Peroxide; Mice; Mitochondria; Neuroblastoma; Neurons; Nitroprusside; Oxidants; Primates; Stroke

Topics: Acute Disease; Antioxidants; Benzenesulfonates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Neuroprotective Agents; Stroke

Topics: Benzenesulfonates; Brain Ischemia; Clinical Trials as Topic; Humans; Neuroprotective Agents; Spin Trapping; Stroke

Topics: Acute Disease; Animals; Benzenesulfonates; Cardiovascular Agents; Drug Evaluation, Preclinical; Humans; Reproducibility of Results; Research Design; Stroke

Topics: Analysis of Variance; Antioxidants; Benzenesulfonates; Humans; Models, Statistical; Odds Ratio; Outcome Assessment, Health Care; Severity of Illness Index; Stroke; Treatment Outcome

Topics: Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Free Radical Scavengers; Humans; Neuroprotective Agents; Stroke

Topics: Animals; Antioxidants; Benzenesulfonates; Brain; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Magnetic Resonance Imaging; Neuroprotective Agents; Practice Guidelines as Topic; Stroke

Topics: Animals; Behavior, Animal; Benzenesulfonates; Blood Cell Count; Body Weight; Brain; Cell Death; Cerebral Hemorrhage; Disease Models, Animal; Free Radical Scavengers; Hematoma; Infusion Pumps; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Motor Skills; Neuroprotective Agents; Neutrophil Infiltration; Nitrogen Oxides; Pilot Projects; Rats; Rats, Sprague-Dawley; Stroke; Treatment Outcome

Topics: Animals; Behavior, Animal; Benzenesulfonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fibrinolytic Agents; Intracranial Embolism; Male; Microspheres; Neuroprotective Agents; Nitrogen Oxides; Rabbits; Spin Trapping; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome

Topics: Animals; Benzenesulfonates; Blood Glucose; Body Temperature; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Intracranial Embolism; Male; Neuroprotective Agents; Nitrogen Oxides; Rabbits; Stroke; Tissue Plasminogen Activator; Treatment Outcome